Dana-Farber Cancer Institute

450 Brookline Avenue
Boston, MA 02215-5450

**COVID-19 Protective Immunity Study – Recruitment Literature (Printed Copy)**

**Have you recovered from COVID-19? We Need Your Help.**

COVID-19 infection imposes significant societal and health burdens. Discovering therapeutic/diagnosis antibodies and developing an effective vaccine would have broad implications for global public health. Your convalescent plasma, which contains antibodies against the virus, could also save a life.

Researchers at Dana-Farber Cancer Institute have launched an initiative to help determine how a person's immune response to COVID-19 is affected by their age, medical history and genetics. They are also interested in determining if you are an elite responder who produces exceptionally high levels of protective antibodies against COVID-19.

**Am I eligible?**

We are enrolling 150 volunteers who have recovered from COVID-19 (i.e. r*esolution of fever, improvement of respiratory symptoms and 2 negative COVID-19 NP tests >24 hours apart)* and will be broadly assigned into one of the following three groups.

Group 1 – Healthcare workers who have directly cared for COVID-19 infected individuals (e.g. ER, clinic, other).

Group 2 – Cancer patients that are at any stage of their cancer illness. Most importantly if you have undergone recent chemo or radiation therapy or immunotherapy.

Group 3 - Individuals who believe they have acquired COVID-19 infection by a route other than direct COVID-19 patient exposure. This group includes physicians and healthcare workers who have no known COVID-19 patient contacts and individuals in the community that have recovered from COVID-19.

**What do I need to do?**
Joining the COVID-19 Protective Immunity Study is simple. Click this link (https://j.mp/3flblXr) to let us know you are interested and leave your contact information so the research nurse can contact you for consent and eligibility screening.

**Remote Consent and on study Review**

- During the phone call, the research nurse will review the consent form with you
- You will have the opportunity to ask any questions you may have.
- The research nurse will send a copy of the consent form via email, fax or USPS mail.

  - If sent via email, the participant should print and sign/date the consent form and scan/email the consent form back to the research nurse email address
  - If sent via fax, the participant should sign/date the consent form and fax the consent form back to the research nurse's provided fax number
  - If sent via USPS mail, the participant will sign/date the consent form on the day they receive the consent form and bring it with them at the time of their appointment if they are eligible
- Once you have provided consent, the research nurse will work with you by phone to complete an online eligibility survey hosted on a HIPPA-compliant server to determine if you meet the requirements to participate in this study. This information will be related to your COVID-19 experience and include information related to your health history.
  - If you do not meet the requirements to join the study, the research nurse will thank you for your time and you will no longer be contacted by the study team.
  - If you do meet the requirements to join the study, the research nurse will set up an appointment for a follow-up questionnaire completion and a visit to the Dana-Farber Cancer Institute (DFCI) for a blood draw.
- Your projected time at DFCI will be approximately 0.5 hour
- You will also be asked to provide a one-time collection of 4 tablespoons of blood via blood draw.

**Is there any compensation for participating?**

Onsite parking and a onetime compensation payment will be arranged for you upon completing your blood draw.

**Where can I find more information?**

Access this website (https://j.mp/3flblXr) and answer the three questions and a research nurse will contact you with more information.

**Who is leading this study?**

Dana-Farber Cancer Institute

Wayne A. Marasco, MD, Ph.D.,
Professor, Department of Cancer Immunology and Virology